Literature DB >> 23873804

The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma.

Brian Patrick O'Neill1, Paul A Decker, Christina Tieu, James R Cerhan.   

Abstract

There has been an overall decline in the United States incidence of Primary CNS Lymphoma (PCNSL) from 1998 to 2008. This study's intent was to characterize the cohorts contributing to it. First, calculated the PCNSL incidence rates from nine Surveillance, Epidemiology, and End Results (SEER) registries for time period 1973 to 2008. Second, examined the time trends overall and by age and gender. Third, used 1992-2008 SEER data from the same registries to obtain overall trends for diffuse large B-cell lymphoma (DLBCL). Last, rates were age-adjusted to the 2000 US standard population and reported per 100,000 person-years. Rates continued to increase in women at all ages and men aged 65 and older. In men aged 20-39 and 40-64 years incidence rates peaked in 1995 and then declined dramatically, stabilizing after 1998. The trends in the incidence of PCNSL over this time frame were significantly different from DLBCL for ages 20-39 (P < 0.001) and 40-64 (P < 0.001) years but were not different for the 65 years and older age group (P = 0.99). The overall PCNSL incidence rate declined since 1995 and was driven primarily by the changing incidence in young and middle-aged men. The rate has continued to increase in men aged 65 years and older and in women. The trends in incidence in the younger age groups over this time period did not parallel those observed for DLBCL.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Nothing to report

Mesh:

Year:  2013        PMID: 23873804      PMCID: PMC4020348          DOI: 10.1002/ajh.23551

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.

Authors:  M Booman; K Szuhai; A Rosenwald; E Hartmann; Hc Kluin-Nelemans; D de Jong; E Schuuring; Pm Kluin
Journal:  J Pathol       Date:  2008-10       Impact factor: 7.996

3.  Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study.

Authors:  A Wikby; P Maxson; J Olsson; B Johansson; F G Ferguson
Journal:  Mech Ageing Dev       Date:  1998-05-15       Impact factor: 5.432

Review 4.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Denise Whitby
Journal:  Cancer Lett       Date:  2011-03-04       Impact factor: 8.679

5.  Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens.

Authors:  Esteban Braggio; Ellen Remstein McPhail; William Macon; M Beatriz Lopes; David Schiff; Mark Law; Stephanie Fink; Debra Sprau; Caterina Giannini; Ahmet Dogan; Rafael Fonseca; Brian Patrick O'Neill
Journal:  Clin Cancer Res       Date:  2011-05-11       Impact factor: 12.531

6.  Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy.

Authors:  C Besson; A Goubar; J Gabarre; W Rozenbaum; G Pialoux; F P Châtelet; C Katlama; F Charlotte; B Dupont; N Brousse; M Huerre; J Mikol; P Camparo; K Mokhtari; M Tulliez; D Salmon-Céron; F Boué; D Costagliola; M Raphaël
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

7.  The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis.

Authors:  Janet E Olson; Carol A Janney; Ravi D Rao; James R Cerhan; Paul J Kurtin; David Schiff; Richard S Kaplan; Brian Patrick O'Neill
Journal:  Cancer       Date:  2002-10-01       Impact factor: 6.860

8.  Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.

Authors:  J L Villano; M Koshy; H Shaikh; T A Dolecek; B J McCarthy
Journal:  Br J Cancer       Date:  2011-09-13       Impact factor: 7.640

9.  AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989-2003.

Authors:  Ingfrid S Haldorsen; Jostein Kråkenes; Anne K Goplen; Oona Dunlop; Olav Mella; Ansgar Espeland
Journal:  BMC Cancer       Date:  2008-08-06       Impact factor: 4.430

  9 in total
  38 in total

1.  Bevacizumab for recurrent primary central nervous system lymphoma: a new treatment?

Authors:  Karina Nieto; Leo I Gordon; Jeffrey Raizer
Journal:  Neuro Oncol       Date:  2015-12       Impact factor: 12.300

2.  Predictive value of microRNAs as novel biomarkers in detection of lymphoma.

Authors:  Yongjing Wang; Dianshui Sun; Juandong Wang; Aixia Dou; Chengyun Zheng
Journal:  Int J Clin Exp Med       Date:  2015-08-15

3.  Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI.

Authors:  Fu-Hua Lin; Xiang-Heng Zhang; Ji Zhang; Zhen-Qiang He; Hao Duan; Chao Ke; Ke Sai; Xiao-Bing Jiang; Fuad Al-Nahari; Shao-Yan Xi; Yong-Gao Mou
Journal:  J Neurooncol       Date:  2018-08-16       Impact factor: 4.130

4.  Risk factors for intraocular involvement in patients with primary central nervous system lymphoma.

Authors:  Bum-Joo Cho; Hyeong Gon Yu
Journal:  J Neurooncol       Date:  2014-08-15       Impact factor: 4.130

5.  Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.

Authors:  Han W Tun; Patrick B Johnston; Lisa M DeAngelis; Pamela J Atherton; Levi D Pederson; Patricia A Koenig; Craig B Reeder; Antonio M Padula Omuro; David Schiff; Brian O'Neill; Jose Pulido; Kurt A Jaeckle; Christian Grommes; Thomas E Witzig
Journal:  Blood       Date:  2018-09-27       Impact factor: 22.113

Review 6.  Updates on Primary Central Nervous System Lymphoma.

Authors:  Lauren R Schaff; Christian Grommes
Journal:  Curr Oncol Rep       Date:  2018-02-28       Impact factor: 5.075

7.  Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database.

Authors:  Jaleh Fallah; Lindor Qunaj; Adam J Olszewski
Journal:  Blood Adv       Date:  2016-11-30

8.  Primary central nervous system lymphoma: is whole-body CT and FDG PET/CT for initial imaging reasonable?

Authors:  Hana Malikova
Journal:  Quant Imaging Med Surg       Date:  2019-09

9.  The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.

Authors:  Joe S Mendez; Quinn T Ostrom; Haley Gittleman; Carol Kruchko; Lisa M DeAngelis; Jill S Barnholtz-Sloan; Christian Grommes
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

10.  Treatment of primary CNS lymphoma.

Authors:  Patrick Roth; Roger Stupp; Günter Eisele; Michael Weller
Journal:  Curr Treat Options Neurol       Date:  2014-01       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.